Inari Medical Reports Third Quarter 2021 Financial Results
Inari Medical (NASDAQ: NARI) reported a record revenue of $72.9 million for Q3 2021, marking a 15% sequential and 88% year-over-year increase. The FDA cleared the ClotTriever Bold Thrombectomy Catheter, expanding treatment options for patients with advanced DVT. The company's gross profit reached $65.9 million, yielding a gross margin of 90.3%. However, operating expenses surged to $68.6 million, primarily due to increased personnel costs and stock-based compensation. Inari's cash reserves stand at $168.6 million. The revenue guidance for 2021 was raised to $266 to $268 million.
- Q3 2021 revenue of $72.9 million, up 15% sequentially and 88% year-over-year.
- FDA clearance for ClotTriever Bold increases treatment options.
- Gross profit of $65.9 million, maintaining a gross margin of 90.3%.
- Increased full-year 2021 revenue guidance to $266 to $268 million.
- Operating expenses rose to $68.6 million due to personnel-related expenses.
- Net loss of $2.8 million for Q3 2021 compared to net income of $6.5 million last year.
IRVINE, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today reported financial results for its third quarter ended September 30, 2021.
Third Quarter Revenue and Business Highlights:
- Treated a record number of patients, with revenue of
$72.9 million for the third quarter of 2021, up15% sequentially and88% year-over-year. - Announced FDA clearance of ClotTriever Bold Thrombectomy Catheter, which is designed to treat older clots and more advanced DVT, potentially opening a large new TAM.
- Presented data from first 500 patients enrolled in the FLASH PE registry, confirming best in class safety and on-table improvement in hemodynamic metrics, while showing much lower rates of mortality and long-term consequences for PE survivors than published literature.
- Ended the quarter with
$168.6 million in cash, cash equivalents and investments.
“Our third quarter was as successful as it was exciting. We again treated a record number of patients and made important progress on all five of our growth drivers,” said Bill Hoffman, CEO of Inari Medical. “We presented data from our FLASH PE registry, confirming outstanding safety and acute efficacy. We believe it also shows, now with six month follow up, that FlowTriever changes the natural course of the disease in life saving and life changing ways. We also received FDA clearance for our ClotTriever Bold which might provide a treatment option for a whole new population of patients suffering the most devastating consequences of previously untreated DVT. We are thankful for the opportunity to serve our patients and our mission.”
Third Quarter 2021 Financial Results
Revenue was
Gross profit was
Operating expenses for the third quarter of 2021 were
Net loss was
Our cash, cash equivalents and investments were
Updated Full-Year 2021 Revenue Guidance
Inari Medical is updating financial guidance as follows:
- For the full-year 2021, revenue guidance is increased to
$266 t o$268 million , up from our previous guidance of$250 t o$255 million .
Webcast and Conference Call Information
Inari Medical will host a conference call to discuss the third quarter 2021 financial results after market close on Tuesday, November 9, 2021 at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. The conference call can be accessed live over the phone (833) 519-1265 for U.S. callers or (914) 800-3838 for international callers, using conference ID: 7775678. The live webinar can be accessed at https://ir.inarimedical.com.
About Inari Medical, Inc.
Inari Medical, Inc. is a medical device company focused on developing innovative products to treat and transform the lives of patients suffering from venous diseases. Inari has developed two minimally-invasive, novel catheter-based mechanical thrombectomy devices that are designed to remove large clots from large vessels and eliminate the need for thrombolytic drugs. The company purpose-built its products for the specific characteristics of the venous system and the treatment of the two distinct manifestations of venous thromboembolism, or VTE: deep vein thrombosis and pulmonary embolism. The ClotTriever system is 510(k)-cleared by FDA and CE marked for the non-surgical removal of clot from peripheral blood vessels, including for the use in the treatment of deep vein thrombosis. The FlowTriever system is 510(k)-cleared by FDA and CE marked for the non-surgical removal of clot from peripheral blood vessels, including for the use in the treatment of pulmonary embolism and clot in transit in the right atrium.
Forward Looking Statements
Statements in this press release may contain “forward-looking statements” that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. Forward-looking statements include financial guidance regarding full year 2021 revenue and the potential impact of COVID-19 on the business, and are based on Inari’s current expectations, forecasts and assumptions, are subject to inherent uncertainties, risks and assumptions that are difficult to predict, and actual outcomes and results could differ materially due to a number of factors. These and other risks and uncertainties include those described more fully in the section titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the period ended December 31, 2020 and in its other reports filed with the U.S. Securities and Exchange Commission. Forward-looking statements contained in this announcement are based on information available to Inari as of the date hereof and are made only as of the date of this release. Inari undertakes no obligation to update such information except as required under applicable law. These forward-looking statements should not be relied upon as representing Inari’s views as of any date subsequent to the date of this press release. In light of the foregoing, investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of Inari.
Investor Contact:
ICR Westwicke
Caroline Corner
Phone +1-415-202-5678
caroline.corner@westwicke.com
INARI MEDICAL, INC.
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)
(in thousands, except share and per share data)
(unaudited)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2021 | 2020 | 2021 | 2020 | |||||||||||||
| Revenue | $ | 72,916 | $ | 38,715 | $ | 193,766 | $ | 91,059 | ||||||||
| Cost of goods sold | 7,040 | 3,228 | 16,477 | 9,420 | ||||||||||||
| Gross profit | 65,876 | 35,487 | 177,289 | 81,639 | ||||||||||||
| Operating expenses | ||||||||||||||||
| Research and development | 12,499 | 5,217 | 32,292 | 11,863 | ||||||||||||
| Selling, general and administrative | 56,104 | 23,080 | 135,899 | 58,353 | ||||||||||||
| Total operating expenses | 68,603 | 28,297 | 168,191 | 70,216 | ||||||||||||
| (Loss) income from operations | (2,727 | ) | 7,190 | 9,098 | 11,423 | |||||||||||
| Other income (expense) | ||||||||||||||||
| Interest income | 27 | 208 | 130 | 409 | ||||||||||||
| Interest expense | (73 | ) | (251 | ) | (220 | ) | (1,060 | ) | ||||||||
| Change in fair value of warrant liabilities | — | — | — | (3,317 | ) | |||||||||||
| Other income (expense) | 30 | (651 | ) | (4 | ) | (651 | ) | |||||||||
| Total other expenses | (16 | ) | (694 | ) | (94 | ) | (4,619 | ) | ||||||||
| (Loss) income before income taxes | (2,743 | ) | 6,496 | 9,004 | 6,804 | |||||||||||
| Provision for income taxes | 61 | — | 271 | — | ||||||||||||
| Net (loss) income | $ | (2,804 | ) | $ | 6,496 | $ | 8,733 | $ | 6,804 | |||||||
| Other comprehensive (loss) income | ||||||||||||||||
| Foreign currency translation adjustments | (146 | ) | — | (269 | ) | — | ||||||||||
| Unrealized (loss) gain on available-for-sale securities | 7 | — | 19 | — | ||||||||||||
| Total other comprehensive loss | (139 | ) | — | (250 | ) | — | ||||||||||
| Comprehensive (loss) income | $ | (2,943 | ) | $ | 6,496 | $ | 8,483 | $ | 6,804 | |||||||
| Net (loss) income per share | ||||||||||||||||
| Basic | $ | (0.06 | ) | $ | 0.13 | $ | 0.18 | $ | 0.26 | |||||||
| Diluted | $ | (0.06 | ) | $ | 0.12 | $ | 0.16 | $ | 0.14 | |||||||
| Weighted average common shares used to compute net (loss) income per share | ||||||||||||||||
| Basic | 50,001,996 | 48,335,443 | 49,664,037 | 26,423,681 | ||||||||||||
| Diluted | 50,001,996 | 55,355,846 | 55,511,061 | 49,940,409 | ||||||||||||
INARI MEDICAL, INC.
Condensed Consolidated Balance Sheets
(in thousands, except share data and par value)
(unaudited)
| September 30, 2021 | December 31, 2020 | |||||||
| Assets | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 81,158 | $ | 114,229 | ||||
| Short-term investments | 81,436 | 49,981 | ||||||
| Accounts receivable, net | 38,916 | 28,008 | ||||||
| Inventories, net | 19,499 | 10,597 | ||||||
| Prepaid expenses and other current assets | 7,141 | 2,808 | ||||||
| Restricted cash | — | 50 | ||||||
| Total current assets | 228,150 | 205,673 | ||||||
| Property and equipment, net | 14,748 | 7,498 | ||||||
| Long-term investments | 6,002 | — | ||||||
| Operating lease right-of-use assets | 42,855 | — | ||||||
| Deposits and other assets | 672 | 583 | ||||||
| Restricted cash | — | 338 | ||||||
| Total assets | $ | 292,427 | $ | 214,092 | ||||
| Liabilities and Stockholders' Equity | ||||||||
| Current liabilities | ||||||||
| Accounts payable | 5,083 | 3,047 | ||||||
| Payroll-related accruals | 16,987 | 8,198 | ||||||
| Accrued expenses and other current liabilities | 6,583 | 2,593 | ||||||
| Operating lease liabilities, current portion | 857 | — | ||||||
| Total current liabilities | 29,510 | 13,838 | ||||||
| Operating lease liabilities, noncurrent portion | 28,547 | — | ||||||
| Total liabilities | 58,057 | 13,838 | ||||||
| Commitments and contingencies (Note 7) | ||||||||
| Stockholders' equity | ||||||||
| Preferred stock, issued and outstanding as of September 30, 2021 and December 31, 2020 | — | — | ||||||
| Common stock, authorized as of September 30, 2021 and December 31, 2020; 50,144,590 and 49,251,614 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively | 50 | 49 | ||||||
| Additional paid in capital | 253,256 | 227,624 | ||||||
| Accumulated other comprehensive (loss) income | (246 | ) | 4 | |||||
| Accumulated deficit | (18,690 | ) | (27,423 | ) | ||||
| Total stockholders' equity | 234,370 | 200,254 | ||||||
| Total liabilities and stockholders' equity | $ | 292,427 | $ | 214,092 | ||||
FAQ
What were Inari Medical's Q3 2021 revenues?
How did Inari Medical's Q3 2021 performance compare year-over-year?
What is Inari Medical's updated revenue guidance for 2021?
What was the net loss reported by Inari Medical in Q3 2021?
